In light of this evidence, in our routine clinical practice, FSHB c.-211G > T polymorphism analysis is used to identify a subgroup of infertile men who will respond well to FSH therapy and who have spermatogenic impairment and low or inappropriately normal FSH plasma levels. This evidence concerns the gene BRD2 and Infertility.